HeartBeam Secures $10 Million in Public Offering, Led by Customer

Event summary

  • HeartBeam (BEAT) closed a public offering of 12.5 million shares, raising $10 million in gross proceeds.
  • The offering was led by HeartBeam’s first commercial customer, ClearCardio, and included participation from executive leadership, board members, existing investors, and institutional investors.
  • Titan Partners, a division of American Capital Partners, served as the sole bookrunner.
  • Proceeds will be allocated to commercialization, product development (extended-wear patch, heart attack detection), AI enhancement, and general corporate purposes.
  • The offering was made under a shelf registration statement filed with the SEC on March 13, 2026, which became effective on March 17, 2026.

The big picture

HeartBeam’s capital raise underscores the ongoing demand for remote cardiac monitoring solutions, driven by an aging population and a shift towards preventative healthcare. The involvement of ClearCardio, a first commercial customer, is a notable validation of HeartBeam’s technology, but also introduces a potential concentration risk. The $10 million raise provides a runway for continued development and commercialization, but the company will need to demonstrate a clear path to sustainable revenue generation.

What we're watching

Customer Alignment
ClearCardio’s participation in the offering signals a degree of confidence in HeartBeam’s technology and potential for integration, but also introduces a dependency that warrants monitoring.
Burn Rate
The allocation of proceeds to multiple initiatives (commercialization, development, AI) suggests a potentially high burn rate, and the company’s ability to achieve profitability will depend on efficient execution and rapid adoption.
Regulatory Risk
While HeartBeam has secured FDA clearances, continued innovation and expansion of its product offerings will remain subject to ongoing regulatory scrutiny and potential delays.